Anaemia and Long Term Mortality in Heart Failure Patients: A Retrospective Study by Charlot, Mette et al.
  The Open Cardiovascular Medicine Journal, 2010, 4, 173-177 173 
 
  1874-1924/10  2010 Bentham Open 
Open Access 
Anaemia and Long Term Mortality in Heart Failure Patients: A   
Retrospective Study 
Mette Charlot
1,*, ChristianTorp-Pedersen
1, Nana Valeur
1, Marie Seibæk
2,  
Peter Weeke
1 and Lars Køber
3 
1Department of Cardiology, Copenhagen University Hospital Gentofte, Hellerup, Denmark 
2Department of Cardiology, Glostrup Hospital, University of Copenhagen, Denmark 
3The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Denmark 
Abstract: Background: Anaemia has been demonstrated as a risk factor in patients with heart failure over periods of a few 
years, but long term data are not available. We examined the long-term risk of anaemia in heart failure patients during 15 
years of follow-up.  
Methods: We evaluated survival data for 1518 patients with heart failure randomized into the Danish Investigations of  
Arrhythmia and Mortality on Dofetilide (DIAMOND) trial. The follow-up time was from 13 to 15 years. After 15 years 
11.5% of the patients were still alive.  
Results: Anaemia was present in 34% of the patients. 264 (17%) had mild, 152 (10%) had moderate and 98 (7%) had  
severe anaemia. Hazard ratio of death for patients with mild anaemia compared with patients with no anaemia was 1.27 
(1.11-1.45, p<0.001), for moderate anaemia 1.48 (1.24-1.77, p<0.001) and for severe anaemia 1.82 (1.47-2.24, p<0.001), 
respectively. In multivariable analyses anaemia was still associated with increased mortality with hazard ratios of 1.19 
(1.04–1.37, p=0.014) for mild anaemia, 1.23 (1.03–1.48, p=0.024) for moderate anaemia and 1.33 (1.07–1.66, p=0.010) 
for severe anaemia, respectively. In landmark analysis the increased mortality for mild anaemia was only significant  
during the first 2 years, while moderate anaemia remained significant for at least 5 years. There were too few patients left 
with severe anaemia after 5 years to evaluate the importance on mortality beyond this time.  
Conclusion: Anaemia at the time of diagnosis of heart failure is an independent factor for mortality during the following 
years but loses its influence on mortality over time.  
Keywords: Anaemia, heart failure, mortality.  
INTRODUCTION 
  Anaemia is common in patients with heart failure (HF) 
and is found in 4%-55% of the patients [1-4]. Many studies 
have demonstrated anaemia to be a risk factor in patients 
with heart failure [5, 6] and anaemia is currently targeted in 
several interventional trials.  
  The majority of the studies evaluating the importance of 
anaemia are only reporting follow up for 2-3 years and just 
one study has a 5 year follow up [2]. To fully understand the 
implications of anaemia and the potentials of correcting 
anaemia it is important to know the risk associated with 
anaemia and HF over an extended period of time. 
  In the present study we therefore report the long-term 
effect of anaemia over 13 to 15 years of follow up. We   
furthermore explore differences in mortality rates between   
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subgroups of anaemic patients in order to identify patients 
with a particularly high risk. We also perform landmark 
analysis to investigate whether the presence of anaemia   
remains significant during follow up. 
MATERIALS AND METHODOLOGY 
Patient Population  
  The current study is based on analysis of survival data 
including 1518 patients that entered into the Danish Investi-
gations of Arrhythmia and Mortality on Dofetilide in Con-
gestive Heart Failure—the DIAMOND-CHF trial. The de-
sign of the study has been described previously [7]. The 
screening population included 5,548 patients, of which 57 
patients were excluded because of misrecorded personal 
data. Four patients were excluded from our study due to 
missing records of haemoglobin level, leaving 1514 for 
analysis. The DIAMOND trial was a multicenter, random-
ized, double-blinded, placebo-controlled study of the effi-
cacy of a novel class III antiarrhythmic agent, dofetilide, in 
patients with acute myocardial infarction (MI) or HF. 174    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Charlot et al. 
34  Danish hospitals participated in the study. All patients 
admitted consecutively to their centres with new or worsen-
ing HF in the period between November 1993 and December 
1995 were screened for entry in the trial. The centres repre-
sent approximately half the hospitals in Denmark that re-
ceive HF patients. Smaller county hospitals as well as uni-
versity teaching hospitals participated, consequently making 
the study population highly representative of hospitalized HF 
patients in Denmark. 
  Inclusion criterias for the DIAMOND-CHF study were  
as follows: Patients should have been in New York Heart 
Association (NYHA) functional class III or IV at some   
time within the preceding month. The initial screening   
consisted of a clinical history, a physical examination,   
and an echocardiogram, which was recorded on videotape 
locally and evaluated in a central laboratory. Wall motion 
index (WMI), was measured using a 16-segment model of 
the left ventricle, and then calculated using a reverse scoring 
system (8). WMI multiplied by 30 gives a rough estimate of 
percent left ventricular ejection fraction and was obtained in 
95% of the patients. Patients
 were eligible for the study if 
they had a WMI
 of no more than 1.2 (corresponding roughly 
to an ejection fraction
 of no more than 35 percent). Patients 
were excluded if they have had an myocardial infarction 
(MI) within seven days before screening, If they had a heart 
rate of
  less than 50 beats per min during waking hours,   
sinoatrial
  block or second- or third-degree atrioventricular 
block that
  was not treated with a pacemaker, a history of 
drug-induced
 proarrhythmia, a corrected QT interval exceed-
ing 460 msec (500
  msec in patients with bundle-branch 
block), a diastolic blood
 pressure of more than 115 mm Hg,  
a systolic blood pressure of
 less than 80 mm Hg, a serum 
potassium level of less than 3.6 mmol/L
 or more than 5.5 
mmol per liter, recent use of
  class I or III antiarrhythmic 
drugs, a calculated creatinine
 clearance rate of less than 20 
ml per min [9], serious liver
 dysfunction, acute myocarditis, 
planned cardiac surgery or angioplasty,
  aortic stenosis,   
cardiac surgery within the preceding four weeks,
  and the 
presence of an implantable cardioverter–defibrillator.
 There 
was no difference in mortality in the two groups of patients 
randomized to dofetilide or placebo.  
  Survival status was obtained from the Danish Central 
Personal Registry in 2008, 15 years after screening of the 
first patient. The follow-up time was 13 to 15 years. Follow-
up was complete. 
DEFINITION OF ANAEMIA  
  Anaemia was defined by the cut-off values defined by the 
World Health Organisation (WHO): haemoglobin (hgb) level 
lower than 120 g/L (corresponding to 7.5 mmol/L) in women 
and 130 g/L (corresponding to 8.0 mmol/L) in men denoted 
as WHO-anaemia throughout the manuscript. In order to 
examine if the prognostic importance of anaemia was driven 
by the subgroup of patients with most severe anaemia, the 
cut-off level of hgb was decreased with 10 and 20 g/L, re-
spectively, resulting in three subgroups of anaemic patients: 
Mild, moderate and severe anaemia. Mild anaemia, corre-
sponding for the first subgroup in each gender, was defined 
as hgb. lower than 120 g/L (6.8 mmol/L) in women, and 
lower than 130 g/L in men. Moderate anaemia was defined 
as hgb. lower than 110 g/L (6.8 mmol/L) in women, and 
lower than 120 g/L in men. And severe anaemia was defined 
as hgb < 100 g/L (6.2 mmol/L) in women and < 110 g/L in 
men. 
STATISTICAL ANALYSES  
  Continuous variables are presented as medians with 5
th 
and 95
th percentiles, and discrete variables as percentages. 
Baseline characteristics were compared using the continuity-
adjusted Chi-square test for discrete variables and analysis of 
continuous variables. Kaplan Meier estimators were used to 
construct mortality curves. Multivariable analysis was per-
formed with Cox proportional hazard models. Hazard ratios 
were obtained from Cox proportional-hazards regression 
using all variables listed in Table 1. Model assumptions 
(proportional hazard, linearity of continuous variables and no 
interaction) were tested and found valid unless otherwise 
reported. Interaction analysis was made in Cox proportional-
hazard models with inclusion of the interaction variable. A p 
value <0.05 was considered significant. All calculations 
were made using SAS software (SAS Institute, Cary, NC, 
USA). 
ETHICS  
  The investigation conforms with the principles outlined 
in the Declaration of Helsinki II and was approved by the 
Central Danish Ethics Committee. All patients gave their 
written, informed consent before enrolment. 
RESULTS  
Patient Characteristics  
  According to the WHO criteria, 1000 (66%) patients had 
no anaemia, 264 (17%) had mild, 152 (10%) had moderate 
and 98 (6%) had severe anaemia. Baseline characteristics are 
shown in Table 1. Anaemia was associated with decreasing 
creatinin clearance, male gender, being smoker and in 
NYHA class IV.  
MORTALITY ANALYSIS  
  Among the patients with no anaemia, 860 (86%) patients 
died during follow up, compared with 239 (91%) patients 
with mild anaemia, 143 (94%) patients with moderate anae-
mia and 97 (99%) patients with severe anaemia. 
  When evaluated in a univariate model, the hazard ratio of 
death for patients with mild anaemia compared with patients 
with no anaemia was 1.27 (1.11-1.45, p<0.001) for moderate 
anaemia 1.48 (1.24-1.77, p<0.001) and for severe anaemia 
1.82 (1.47-2.24, p<0.001), respectively. To investigate 
whether the increased mortality in patients with anaemia 
reflected a higher prevalence of concomitant risk factors, a 
multivariable analysis, including age, gender, smoking, his-
tory of ischemic heart disease, previous MI, arterial hyper-
tension, atrial fibrillation, NYHA functional class, WMI and 
creatinine clearance as covariates, was performed. Anaemia 
was still found to be a significant prognostic predictor of 
mortality with a hazard ratio of 1.19 (1.04–1.37, p=0.014) 
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anaemia and 1.33 (1.07–1.66, p=0.010) for severe anaemia, 
respectively (Figs. 1 and 2).  
  Suspecting that anaemia loses its influence on mortality 
over time we performed a multivariable proportional hazard 
regression model investigating the mortality for predefined 
periods of time after the diagnosis. It confirmed that the   
increased mortality for mild and severe anaemia only was 
significant in the first two years with a hazard ratio of 1.34 
(1.11-1.62, p=0.003) and 1.44 (1.07-1.93, p=0.015) respec-
tively and the increased mortality for moderate anaemia   
was significant in the first five years, hazard ratio 1.46 (1.06-
2.02, p=0.021) (Table 2, Fig. 3).  
DISCUSSION 
Prevalence  
  In our study, anaemia was frequently observed, found in 
over one-third of HF patients. This is similar to previously 
Table 1.  Baseline Characteristics 
  No Anaemia (n=1000)  Mild Anaemia (n=264)  Moderate Anaemia (n=152)  Severe Anaemia (n=98)  p-value 
Age   68.4 (0.32)  72.3 (0.58)  72.7 (0.69)  73.2 (0.89)  <0.001 
Weight   77.2 (0.48)  71.7 (0.92)  69.2 (1.09)  69.4 (1.25)  <0.001 
WMI   0.87 (0.01)  0.85 (0.02)  0.87 (0.02)  0.90 (0.02)  0.33 
Creatinine clearance   61.6 (0.79)  50.0 (1.29)  46.2 (1.35)  43.6 (1.72)  <0.001 
Sex, male  804 (81%)  157 (60%)  84 (55%)  65 (66%)  <0.001 
Smoker  365 (37%)  73 (28%)  47 (31%)  33 (34%)  0.04 
History of:  
Prior AMI  507 (51%)  135 (51%)  81 (53%)  54 (55%)  0.82 
AF  210 (21%)  39 (15%)  31 (20%)  16 (16%)  0.12 
Hypertension  157 (15%)  36 (14%)  19 (13%)  10 (10%)  0.36 
NYHA III  518 (52%)  147 (56%)  80 (53%)  59 (61%)  0.25 
NYHA IV  51 (5%)  21 (8%)  20 (13%)  7 (7%)  0.003 
Betablocker  96 (10%)  30 (11%)  16 (11%)  10 (10%)  0.85 
ACE-inhibitor  767 (77%)  184 (70%)  103 (68%)  73 (75%)  0.02 
Diuretics  951 (95%)  257 (97%)  159 (98%)  92 (94%)  0.16 
Data are presented as mean, standard deviation (SD), number of patients (n) or percentages. WMI =Wall Motion Index. AMI = Acute Myocardial Infarction. AF = Atrial Fibrillation. 
NYHA = The New York Heart Association Functional Classification. ACE = Angiotensin Converting Enzyme. 
 
Fig. (1). Hazard Ratio all cause death. Hazard ratios for death associated with anaemia in patients with chronic heart failure. Cox propor-
tional hazards regression analysis adjusted for age, gender, smoking, history of ischemic heart disease, previous MI, arterial hypertension, 
atrial fibrillation, NYHA functional class, WMI and creatinine clearance. Bars indicate 95% confidence intervals. 176    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Charlot et al. 
observed frequencies [1-4] emphasising that a large part of 
the patient population with HF has anaemia as a possible 
factor of co-morbidity. 
 
Fig. (2). Mortality rates rates full follow up. Kaplain-Meier   
cumulative hazard estimates. 
MORTALITY  
  This is, to our knowledge, the first long term study be-
yond 5 years of the prognostic importance of anaemia in 
patients with chronic heart failure. Other reports have de-
scribed the prevalence and prognostic importance of anaemia 
in patients HF. However, these studies were based on rela-
tively short periods of observation. In a recent meta-analysis 
with a follow up from 6 months to 5 years [2], anaemia was 
found to be an independent predictor of mortality HR 1.46 
(1.26-1.69) p<0.001).  
  The present study extends previous reports by investigat-
ing the increased mortality risk related to anaemia at the time 
of diagnosis of heart failure is present during the following 
13 to 15 years. We conclude that anaemia is an independent 
risk factor for mortality in HF patients, when assessing the 
mortality risk by using multivariable analyses. Furthermore, 
when assessing the importance of the severity of anaemia, 
we found that the mortality risk increased with the severity 
of the anaemia. 
 
Fig. (3). Mortality rates in land mark analysis. Kaplain-Meier 
cummulative hazard estimates. 
  While we had a follow up of 13 to 15 years mild anaemia 
only had a short term influence on mortality while moderate 
anaemia remained an independent factor of mortality for at 
least 5 years. In the group of patients with severe anaemia 
mortality was particularly high resulting in the fact that there 
were too few patients left after 5 years too significantly 
evaluate the importance on mortality beyond this time.  
  In this study there were no signs of cancer at the time of 
inclusion leading to the argument that anaemia in the in-
cluded patients was caused by chronic disease e.g. kidney 
disease. This is illustrated in our study by the fact that the 
more severe the anaemia the lower the creatinine clearance.  
PERSPECTIVES  
  It is of great importance to know the long-term mortality 
risk for anaemic HF patients over an extended period of time 
in order to properly assess the risk-benefit of potentially cor-
recting anaemia. 
  Anaemia is a novel therapeutic target in the treatment of 
HF patients though it still remains controversial whether to 
treat anaemia in patients with heart failure. The focus is on 
treatment with intravenous iron treatment and erythropoiesis-
Table 2.  Hazard Ratio for Death 
  Mild Anaemia  Moderate Anaemia  Severe Anaemia 
0-2 years  1.34 (1.11-1.61, p = 0.003)  1.22 (0.95-1.56, p = 0.115)  1.44 (1.07-1.92, p = 0.015) 
2-5 years  1.13 (0.88-1.46, p = 0.34)  1.46 (1.06-2.01, p = 0.021)  1.10 (0.71-1.69, p = 0.67) 
5-10 years  0.97 (0.72-1.30, p = 0.82)  0.93 (0.58-1.50, p = 0.76)  1.48 (0.91-2.42, p = 0.11) 
Hazard ratio and 95% confidence interval. Anaemia and Mortality in Heart Failure Patients  The Open Cardiovascular Medicine Journal, 2010, Volume 4    177 
stimulating proteins to increase haemoglobin levels. There 
are several promising randomized trials investigating treat-
ment with erythropoietin or darbepoitin with or without in-
travenous iron therapy versus placebo [10-14]. In relation to 
these trials there has recently been raised concern about the 
possibility of increased risk of tromboembolic events when 
raising haemoglobin levels. Currently a larger phase III trial 
is evaluating treatment of anaemic patients with heart failure 
with darbepoetin [15, 16]. 
LIMITATIONS AND STRENGTHS  
  Some limitations should be acknowledged. First, this 
study is retrospective. Second, generalisation of these data to 
other racial and ethnic groups should be cautious due to the 
fact that the Danish population remains largely white Cauca-
sian. Second, information on the cause of anaemia, including 
ferritin and transferring levels, was not available for analysis. 
Third, a recent study [17] with serial haemoglobin measure-
ments showed that persistent anaemia has a larger effect on 
mortality than transient anaemia. In our study the level of 
haemoglobin was not measured during follow-up, thus it 
remains unknown whether anaemia in the population was 
persistent or transient as well as there is no information 
about possible treatment of the anaemia.  
  The present study is strengthened by its very large sam-
ple size and by the fact that no patients were lost to follow-
up. 
CONCLUSION 
  The present study concludes that anaemia is present in 
one third of patients at the time of diagnosis of heart failure 
and that anaemia at the time of diagnosis of heart failure is 
an independent factor for mortality in the following 2-5 
years. The presence of mild or severe anaemia loses its in-
fluence on mortality after 2 years while moderate anaemia 
loses its influence on mortality after 5 years. 
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